Institute of Nuclear Medicine and Allied Sciences, IndiaReceived Date: 2022-01-05 | Accepted Date: 2022-01-10 | Published Date: 2022-01-14
Institute of Nuclear Medicine and Allied Sciences, India\
Received: January 05, 2022; Accepted: January 10, 2022; Published: : January 14, 2022
Hematopoietic stem and progenitor cells (HSPCs) are the key regulators of hematopoiesis which give rise to different, mature and committed lineages. Exposure to acute whole- body radiation results in the loss of HSPCs leading to the inability of the system to generate differentiated lineages which ultimately cause hematopoietic form of acute radiation syndrome (hs-ARS). Currently no safe and effective molecule as a radiation countermeasure is available for human applications. Due to this bone marrow transplantation (BMT) has become an indispensable strategy for the management of radiation over-exposed victims, hematopoietic malignancies and planned chemotherapy induced bone marrow depression. Several strategies have been employed to achieve successful Hematopoietic stem cell transplantation (HSCT), capable of enhancing HSC homing and engraftment potential but at a high cost. Here in this study, we have reported an inexpensive strategy involving short- term ex-vivo exposure of bone marrow mononuclear cells (BMMNCs) to a small molecule which successfully enhances the HSPCs proliferation, migration and homing to its BM niche after transplantation. Results indicate that ex-vivo exposure led to a significant increase in CXCR4 expression and migration of HSPCs towards SDF-1α as evident from in-vitro studies. In-vivo data displayed that ex-vivo exposure of BMMNCs with the molecule resulted in a significant increase in the number of homed cells to the BM niche as compared to the vehicle treated group. Hence, the above strategy suggests an efficient and cost-effective method for achieving successful HSC transplantation for a variety of scenarios including management of hs-ARS.